Assessment of the complexity of BTH in PNH patients receiving complement inhibitors, particularly in the setting of TPE and transfusion is provided, particularly in the setting of TPE and transfusion.
Abstract
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59. Their absence leads to complement‐mediated intravascular hemolysis. Patients may present with anemia, hemoglobinuria, renal injury, and potentially life‐threatening thromboses. Complement inhibitors have transformed treatment for PNH. Terminal complement inhibitors reduce intravascular hemolysis and transfusion requirements but do not prevent C3‐mediated extravascular hemolysis. Proximal complement inhibitors address both intravascular and extravascular hemolysis, but some are associated with a higher risk of breakthrough hemolysis (BTH). This article describes a transfusion‐independent PNH patient on pegcetacoplan who developed severe BTH post‐HLA desensitization using therapeutic plasma exchange (PLE) prior to hematopoietic cell transplantation. Methods The authors reflect on several potential contributors including iatrogenic removal of pegcetacoplan, TPE, IVIG, and ABO‐mismatched platelets, offering guidance on reducing the risk of BTH and potential management strategies. Results The authors provide a detailed description of the patient case, discussing bio‐, pharmacologic‐, and transfusion‐related factors which may promote BTH in PNH patients. Conclusion This article provides the authors' assessments highlighting the complexity of BTH in PNH patients receiving complement inhibitors, particularly in the setting of TPE and transfusion. Evaluation should consider potential precipitants of BTH, including iatrogenic drug removal and complement‐amplifying conditions such as transfusions. Adjunctive C5 inhibition may be required in acute settings, and further studies are needed to define optimal dosing strategies.
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated hemolysis. Although C5 inhibitors effectively control intravascular hemolysis, some patients develop clinically significant extravascular hemolysis (EVH) because of upstream C3 deposition. A 56-year-old woman was diagnosed with PNH in 201...
Yewon Park, Hyunju Lee· Blood Research· 0 citations
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematologic disorder characterized by complement-mediated intravascular hemolysis, pancytopenia, and thrombosis. NTQ5082 is a novel oral selective complement factor B (CFB) inhibitor that suppresses alternative pathway activity, thereby inhibiting intravascular hemo...
Li Zhang, Gai-Xiang Xu, Ling-Hui Xia et al.· American journal of hematolo...· 0 citations
Iptacopan served as a bridge to control hemolysis, while the subsequent addition of IST addressed the underlying autoimmune bone marrow failure and no breakthrough hemolysis, extravascular hemolysis, or drug-related adverse events were observed.
Xiao-Qian Liu, Jie Xu, Ya-Qin Luo et al.· Medicine· 0 citations
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal bone marrow disorder caused by a mutation in the PIG-A gene and a deficiency of GPI-anchor proteins on the surface of blood cells. The clinical picture is characterized by chronic intravascular hemolysis, cytopenias, and thrombotic complications. Dia...
N. Chichkova, M. D. Madoyan, A. Aga et al.· Meditsinskiy sovet = Medical...· 0 citations
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra ‐ orphan life ‐ threatening disorder characterized by chronic intravascular hemolysis (IVH) and thrombosis. 1 Prior to eculizumab approval, patients with PNH had a median survival of between 10 and 22 years 2,3 with thrombosis accounting for 22% – 67% of death in ca...
Morag Griffin, Richard J. Kelly, Colm Bradley et al.· HemaSphere· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.